ATE205724T1 - Vakzine mit einem polysaccharide antigen- trägerprotein konjugat und freien trägerprotein - Google Patents

Vakzine mit einem polysaccharide antigen- trägerprotein konjugat und freien trägerprotein

Info

Publication number
ATE205724T1
ATE205724T1 AT96920790T AT96920790T ATE205724T1 AT E205724 T1 ATE205724 T1 AT E205724T1 AT 96920790 T AT96920790 T AT 96920790T AT 96920790 T AT96920790 T AT 96920790T AT E205724 T1 ATE205724 T1 AT E205724T1
Authority
AT
Austria
Prior art keywords
carrier protein
vaccine
polysaccharide antigen
present
free
Prior art date
Application number
AT96920790T
Other languages
English (en)
Inventor
Moncef Mohamed Slaoui
Pierre Hauser
Original Assignee
Smithkline Beecham Biolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27451300&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE205724(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9512827.8A external-priority patent/GB9512827D0/en
Priority claimed from GBGB9513443.3A external-priority patent/GB9513443D0/en
Priority claimed from GBGB9525657.4A external-priority patent/GB9525657D0/en
Application filed by Smithkline Beecham Biolog filed Critical Smithkline Beecham Biolog
Application granted granted Critical
Publication of ATE205724T1 publication Critical patent/ATE205724T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/13—Poliovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
AT96920790T 1995-06-07 1996-06-04 Vakzine mit einem polysaccharide antigen- trägerprotein konjugat und freien trägerprotein ATE205724T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US47263995A 1995-06-07 1995-06-07
GBGB9512827.8A GB9512827D0 (en) 1995-06-23 1995-06-23 Vaccines
GBGB9513443.3A GB9513443D0 (en) 1995-07-01 1995-07-01 Vaccines
GBGB9525657.4A GB9525657D0 (en) 1995-12-15 1995-12-15 Vaccines
PCT/EP1996/002436 WO1996040242A1 (en) 1995-06-07 1996-06-04 Vaccine comprising a polysaccharide antigen-carrier protein conjugate and free carrier protein

Publications (1)

Publication Number Publication Date
ATE205724T1 true ATE205724T1 (de) 2001-10-15

Family

ID=27451300

Family Applications (2)

Application Number Title Priority Date Filing Date
AT96920790T ATE205724T1 (de) 1995-06-07 1996-06-04 Vakzine mit einem polysaccharide antigen- trägerprotein konjugat und freien trägerprotein
AT00203772T ATE400295T1 (de) 1995-06-07 1996-06-04 Vakzine mit einem polysaccharide antigen- trägerprotein konjugat und freiem trägerprotein

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT00203772T ATE400295T1 (de) 1995-06-07 1996-06-04 Vakzine mit einem polysaccharide antigen- trägerprotein konjugat und freiem trägerprotein

Country Status (18)

Country Link
EP (2) EP1090642B8 (de)
JP (2) JP4233113B2 (de)
AT (2) ATE205724T1 (de)
AU (1) AU695720B2 (de)
BR (1) BR9608612A (de)
CA (1) CA2221511C (de)
CZ (1) CZ390297A3 (de)
DE (2) DE69637597D1 (de)
DK (1) DK1090642T3 (de)
ES (2) ES2164251T5 (de)
HU (1) HUP9802199A3 (de)
IL (1) IL122431A0 (de)
NO (1) NO975555L (de)
NZ (1) NZ311000A (de)
PT (1) PT1090642E (de)
SI (1) SI1090642T1 (de)
TR (1) TR199701547T1 (de)
WO (1) WO1996040242A1 (de)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696065B1 (en) 1995-05-04 2004-02-24 Aventis Pastuer Limited Acellular pertussis vaccines and methods of preparation thereof
EP1090642B8 (de) * 1995-06-07 2010-08-11 GlaxoSmithKline Biologicals s.a. Vakzine mit einem Polysaccharide Antigen-Trägerprotein Konjugat und freiem Trägerprotein
EP1762246A1 (de) * 1996-07-02 2007-03-14 Sanofi Pasteur Limited Vielwertige DTP-Polio-Impfstoffe
US6248334B1 (en) 1997-01-08 2001-06-19 Henry M. Jackson Foundation For The Advancement Of Military Medicine Process for preparing conjugate vaccines including free protein and the conjugate vaccines, immunogens, and immunogenic reagents produced by this process
DE69940338D1 (de) 1998-02-05 2009-03-12 Jackson H M Found Military Med Vereinfachte methode zur entfernung von freiem protein während der herstellung von protein-polysaccharid-konjugaten und impfstoffen unter verwendung von medien mit limitierter durchlässigkeit
US7018637B2 (en) * 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
MY125387A (en) 1999-03-19 2006-07-31 Smithkline Beecham Biologicals S A Vaccine
FR2806304B1 (fr) * 2000-03-17 2002-05-10 Aventis Pasteur Conjugues polysaccharidiques du pneumocoque a usage vaccinal contre le tetanos et la diphterie
CN100556459C (zh) 2001-01-23 2009-11-04 安万特巴斯德公司 多价脑膜炎球菌多糖-蛋白质缀合疫苗
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
JP4697706B2 (ja) 2002-10-11 2011-06-08 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル 高毒性髄膜炎菌系統に対する広範な防御のためのポリペプチド−ワクチン
AR041880A1 (es) 2002-11-01 2005-06-01 Glaxosmithkline Biolog Sa Composicion inmunogena
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
CA3042073C (en) 2003-01-30 2022-09-13 Novartis Vaccines And Diagnostics S.R.L. Injectable vaccines against multiple meningococcal serogroups
ATE517091T1 (de) 2003-09-26 2011-08-15 Exelixis Inc C-met-modulatoren und verwendungsverfahren
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
JP4738339B2 (ja) 2003-10-02 2011-08-03 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル 複数の髄膜炎菌血清群についての液体ワクチン
GB0406013D0 (en) 2004-03-17 2004-04-21 Chiron Srl Analysis of saccharide vaccines without interference
EP1740217B1 (de) 2004-04-30 2011-06-15 Novartis Vaccines and Diagnostics S.r.l. Meningokokken-konjugat-impfung
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
GB0411387D0 (en) 2004-05-21 2004-06-23 Chiron Srl Analysis of saccharide length
GB0413868D0 (en) 2004-06-21 2004-07-21 Chiron Srl Dimensional anlaysis of saccharide conjugates
GB0428394D0 (en) * 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
GB0502096D0 (en) 2005-02-01 2005-03-09 Chiron Srl Purification of streptococcal capsular polysaccharide
GB0505518D0 (en) 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
SG175456A1 (en) 2005-04-18 2011-11-28 Novartis Vaccines & Diagnostic Expressing hepatitis b virus surface antigen for vaccine preparation
CN103083657B (zh) 2005-06-27 2016-06-08 葛兰素史密丝克莱恩生物有限公司 免疫原性组合物
WO2007026249A2 (en) 2005-09-01 2007-03-08 Novartis Vaccines And Diagnostics Gmbh & Co Kg Multiple vaccination including serogroup c meningococcus
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
TR201807355T4 (tr) 2006-03-22 2018-06-21 Glaxosmithkline Biologicals Sa Meningokokkal konjugatlarla immünizasyon rejimleri.
US10828361B2 (en) 2006-03-22 2020-11-10 Glaxosmithkline Biologicals Sa Regimens for immunisation with meningococcal conjugates
CA2662064A1 (en) 2006-09-07 2008-03-13 Glaxosmithkline Biologicals S.A. Method of producing a combination polivirus vaccine
GB0700136D0 (en) 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
CN102264444B (zh) 2008-10-27 2015-08-05 诺华股份有限公司 纯化方法
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
AU2010352695B2 (en) 2009-09-30 2014-08-21 Glaxosmithkline Biologicals S.A. Conjugation of Staphylococcus aureus type 5 and type 8 capsular polysaccharides
US9060965B2 (en) 2009-10-30 2015-06-23 Glaxosmithkline Biologicals Sa Purification of Staphylococcus aureus type 5 capsular saccharides
US9173954B2 (en) 2009-12-30 2015-11-03 Glaxosmithkline Biologicals Sa Polysaccharide immunogens conjugated to E. coli carrier proteins
US20130071422A1 (en) 2010-03-18 2013-03-21 Michele Pallaoro Adjuvanted vaccines for serogroup b meningococcus
WO2012031271A1 (en) 2010-09-04 2012-03-08 Novartis Ag Bactericidal antibody assays to assess immunogenicity and potency of meningococcal capsular saccharide vaccines
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
EP2655389A2 (de) 2010-12-24 2013-10-30 Novartis AG Verbindungen
CN103533954B (zh) 2011-03-02 2015-09-09 诺华股份有限公司 含较低剂量的抗原和/或佐剂的联合疫苗
GB201106340D0 (en) * 2011-04-14 2011-06-01 Isis Innovation Composition
US9358284B2 (en) 2011-09-14 2016-06-07 Glaxosmithkline Biologicals Sa Methods for making saccharide-protein glycoconjugates
CA2854934A1 (en) 2011-11-07 2013-05-16 Novartis Ag Carrier molecule comprising a spr0096 and a spr2021 antigen
DE102011122891B4 (de) 2011-11-11 2014-12-24 Novartis Ag Fermentationsmedium, das frei von tierischen Bestandteilen ist, zur Herstellung von Diphtherie-Toxoiden zur Verwendung bei der Impfung von Menschen
EP2592137A1 (de) 2011-11-11 2013-05-15 Novartis AG Fermentierungsmedium ohne Bestandteile tierischen Ursprungs zur Herstellung von Diphtherie-Impfstoffen zur menschlichen Impfung
DE102011118371B4 (de) 2011-11-11 2014-02-13 Novartis Ag Zur Impfung von Menschen geeignete Zusammensetzung, die ein Diphtherie-Toxoid umfasst, sowie Verfahren zu deren Herstellung
GB2495341B (en) 2011-11-11 2013-09-18 Novartis Ag Fermentation methods and their products
GB201121301D0 (en) 2011-12-12 2012-01-25 Novartis Ag Method
EP2822584A1 (de) 2012-03-08 2015-01-14 Novartis AG Kombinationsimpfstoffe mit tlr4-agonisten
ES2820898T3 (es) 2012-05-22 2021-04-22 Glaxosmithkline Biologicals Sa Conjugado del serogrupo X de meningococos
RU2015106930A (ru) 2012-09-06 2016-10-20 Новартис Аг Комбинированные вакцины с менингококком серогруппы в и к/д/с
WO2014053612A1 (en) 2012-10-03 2014-04-10 Novartis Ag Immunogenic composition
JP6440619B2 (ja) 2012-10-12 2018-12-19 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 混合ワクチン用の架橋されていない無細胞百日咳抗原
US20150320852A1 (en) 2012-12-18 2015-11-12 Glaxosmithkline Biologicals Sa Conjugates for protecting against diphtheria and/or tetanus
WO2014107652A2 (en) 2013-01-04 2014-07-10 Obi Pharma Vaccines with higher carbohydrate antigen density and novel saponin adjuvant
CN104174019A (zh) * 2014-09-23 2014-12-03 成都康华生物制品有限公司 四价脑膜炎球菌多糖载体蛋白结合疫苗
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
EP3034516A1 (de) 2014-12-19 2016-06-22 Novartis AG Reinigung von Streptokokkenkapselpolysaccharid
WO2017175082A1 (en) 2016-04-05 2017-10-12 Gsk Vaccines S.R.L. Immunogenic compositions
JP6944946B2 (ja) 2016-10-20 2021-10-06 Ｋｍバイオロジクス株式会社 低分子化ＰＲＰを用いたＨｉｂコンジュゲートワクチンの製造方法
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
EP3799884A1 (de) 2019-10-01 2021-04-07 GlaxoSmithKline Biologicals S.A. Immunogene zusammensetzungen
JP2023548935A (ja) 2020-11-13 2023-11-21 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 新規担体及びコンジュゲーション法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4902506A (en) * 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
US4644059A (en) * 1982-07-06 1987-02-17 Connaught Laboratories, Inc. Haemophilus influenzae B polysaccharide-diptheria toxoid conjugate vaccine
IT1187753B (it) * 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
EP0504202B1 (de) * 1989-12-14 1995-05-03 National Research Council Of Canada Verbessertes meningokokkale polysaccharidkonjugatvakzin
ZA937034B (en) * 1992-09-24 1995-06-23 Brigham & Womens Hospital Group B streptococcus type II and type V polysaccharide-protein conjugate vaccines
EP0594950B1 (de) * 1992-10-27 1999-01-27 American Cyanamid Company Pädiatrische Kombinationsvakzine mit verbesserter Immunogenizität jeder Vakzine komponente
EP1090642B8 (de) * 1995-06-07 2010-08-11 GlaxoSmithKline Biologicals s.a. Vakzine mit einem Polysaccharide Antigen-Trägerprotein Konjugat und freiem Trägerprotein

Also Published As

Publication number Publication date
ES2164251T5 (es) 2006-06-01
JPH11507026A (ja) 1999-06-22
NZ311000A (en) 1999-04-29
IL122431A0 (en) 1998-06-15
CZ390297A3 (cs) 1998-05-13
EP0831901A1 (de) 1998-04-01
HUP9802199A1 (hu) 1999-01-28
MX9709732A (es) 1998-10-31
JP4653131B2 (ja) 2011-03-16
EP0831901B2 (de) 2005-12-07
AU6222196A (en) 1996-12-30
SI1090642T1 (sl) 2008-12-31
EP1090642B1 (de) 2008-07-09
DE69615362T3 (de) 2006-07-20
AU695720B2 (en) 1998-08-20
WO1996040242A1 (en) 1996-12-19
ATE400295T1 (de) 2008-07-15
BR9608612A (pt) 1999-05-04
EP1090642A3 (de) 2001-08-22
CA2221511A1 (en) 1996-12-19
ES2308962T3 (es) 2008-12-16
HUP9802199A3 (en) 1999-07-28
EP0831901B1 (de) 2001-09-19
DE69637597D1 (de) 2008-08-21
NO975555D0 (no) 1997-12-02
EP1090642A2 (de) 2001-04-11
TR199701547T1 (xx) 1998-03-21
PT1090642E (pt) 2008-09-09
NO975555L (no) 1998-01-09
JP4233113B2 (ja) 2009-03-04
EP1090642B8 (de) 2010-08-11
DE69615362T2 (de) 2002-06-13
DK1090642T3 (da) 2008-09-22
ES2164251T3 (es) 2002-02-16
JP2007186524A (ja) 2007-07-26
DE69615362D1 (de) 2001-10-25
CA2221511C (en) 2013-01-08

Similar Documents

Publication Publication Date Title
ATE400295T1 (de) Vakzine mit einem polysaccharide antigen- trägerprotein konjugat und freiem trägerprotein
ZA93945B (en) Dual carrier immunogenic construct.
BR0013814A (pt) Métodos de tratamentos de um paciente humano suscetìvel a ou diagnosticado com uma doença com anticorpos anti-erbb2, artigos industrializados, métodos de tratamentos de câncer em pacientes humanos e usos do anticorpo anti-erbb2
DE69921178D1 (de) Hapten-träger-konjugate zur behandlung und vorbeugung von nikotinabhängigkeit
BRPI0009163B8 (pt) composição imunogênica e vacina que a compreende
BR9106963A (pt) Suave da pele com coadjuvane de silicone para umidificacao/suavizacao da pele
ATE210127T1 (de) 6-substituierte mycophenolsäurederivate mit immun suppressiver wirkung
BR9507400A (pt) Composições imunogénicas de polissacaridio streptococal grupo a e processos
RU92016463A (ru) Применение производных цистина для изготовления лекарственных препаратов с иммуномоделирующим действием, фармацевтические композиции на их основе
DE69228474T2 (de) STABILISIERTE AUFBEREITUNG MONOKLONALER MENSCHLICHER CLN-IgG ANTIKÖRPER
CA2145397A1 (en) Group b streptococcus type ii and type v polysaccharide-protein conjugate vaccines
DE69025691D1 (de) Einschlusskomplexe mit Silybinin, ihre Herstellung und pharmazeutische Präparate, die diese enthalten
DK0406745T3 (da) Antibiotiske GE 2270 faktorer A1, A2, A3 og H
DE69503724T2 (de) L-Carnitin-Salz, dieses enthaltende kosmetische und pharmazeutische Zusammensetzungen zur Behandlung von Dermatosen
ATE359814T1 (de) Zusammensetzung, enthaltend bakterielle antigene, zum vorbeugen und behandeln von allergischen erkrankungen
DE69832197D1 (de) Rantes mutanten und deren therapeutische verwendungen
SE8802323D0 (sv) 8alfa-acylaminoergoline, its preparation and pharmaceutical compositions containing it
MX9710521A (es) Una composicion de vacuna comprendiendo un antigeno conjugado de polisacarido adsorbido en fosfato de aluminio.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties